Adagene Inc

NASDAQ ADAG

Data sourced from

and

Download Data

Adagene Inc Quick Ratio 1 year YoY Change (%) for the year ending December 31, 2021: -56.91%

Adagene Inc Quick Ratio 1 year YoY Change (%) is -56.91% for the year ending December 31, 2021. The quick ratio, also known as the acid-test ratio, measures a company's ability to meet its short-term obligations using its most liquid assets. It is calculated by dividing the current assets minus inventory by the current liabilities. This ratio provides insights into the company's liquidity position and its ability to pay off current liabilities without relying on inventory sales. A higher ratio suggests a stronger ability to meet short-term obligations with readily available assets. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Adagene Inc Quick Ratio for the year ending December 31, 2021 was 6.24.
Adagene Inc Quick Ratio for the year ending December 31, 2019 was 14.47.

NASDAQ: ADAG

Adagene Inc

CEO	Dr. Peter P. Luo Ph.D.
IPO Date	Feb. 9, 2021
Location	China
Headquarters	Building C14, Suzhou, China, 215123
Employees	174
Sector	Healthcare
Industry	Biotechnology

Description

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Key trends